Overview

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Status:
Recruiting
Trial end date:
2025-10-10
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche